High levels of persistent expression of α1-Antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

Bishnu P. De, Adriana Heguy, Neil R. Hackett, Barbara Ferris, Philip L. Leopold, John Lee, Lorraine Pierre, Guangping Gao, James M. Wilson, Ronald Crystal

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

α1-Antitrypsin (α1AT) deficiency is a genetic disorder causing emphysema if serum α1AT levels are <570 μg/ml. We have shown that intrapleural administration of an AAV5α1AT vector yielded persistent therapeutic α1AT serum levels. Since anti-AAV2 and -AAV5 antibodies prevalent in humans may limit the use of these common serotypes in gene therapy, we screened 25 AAV vectors derived from humans and nonhuman primates for α1AT expression following intrapleural administration to mice. The rhesus AAVrh.10 serotype yielded the highest levels and was chosen for further study. Following intrapleural administration, 77% of total body transgene expression was in the chest wall, diaphragm, lung, and heart. Intrapleural administration of AAVrh.10α1AT provided long-term, therapeutic α1AT expression in mice, although higher doses were required to achieve therapeutic levels in female mice than in male mice. Intrapleural administration of AAVrh.10α1AT produced the same levels in AAV2/AAV5-preimmune and naive mice. In mice administered with AAV5α1AT and subsequently "boosted" with the AAVrh.10α1AT vector, serum levels were increased by 300%. These data indicate that AAVrh.10 is the most effective known AAV vector for intrapleural gene delivery and has the advantage of circumventing human immunity to AAV.

Original languageEnglish
Pages (from-to)67-76
Number of pages10
JournalMolecular Therapy
Volume13
Issue number1
DOIs
Publication statusPublished - 1 Jan 2006
Externally publishedYes

Fingerprint

Dependovirus
Primates
Immunity
Serum
Inborn Genetic Diseases
Emphysema
Thoracic Wall
Diaphragm
Transgenes
Genetic Therapy
Serogroup
Therapeutics
Lung
Antibodies
Genes

Keywords

  • α1-antitrypsin
  • Adeno-associated virus
  • Gene therapy
  • Neutralizing antibodies
  • Pleura
  • Serotypes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

High levels of persistent expression of α1-Antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. / De, Bishnu P.; Heguy, Adriana; Hackett, Neil R.; Ferris, Barbara; Leopold, Philip L.; Lee, John; Pierre, Lorraine; Gao, Guangping; Wilson, James M.; Crystal, Ronald.

In: Molecular Therapy, Vol. 13, No. 1, 01.01.2006, p. 67-76.

Research output: Contribution to journalArticle

De, Bishnu P. ; Heguy, Adriana ; Hackett, Neil R. ; Ferris, Barbara ; Leopold, Philip L. ; Lee, John ; Pierre, Lorraine ; Gao, Guangping ; Wilson, James M. ; Crystal, Ronald. / High levels of persistent expression of α1-Antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. In: Molecular Therapy. 2006 ; Vol. 13, No. 1. pp. 67-76.
@article{cceed864969b43edb50cac2e5fff100f,
title = "High levels of persistent expression of α1-Antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses",
abstract = "α1-Antitrypsin (α1AT) deficiency is a genetic disorder causing emphysema if serum α1AT levels are <570 μg/ml. We have shown that intrapleural administration of an AAV5α1AT vector yielded persistent therapeutic α1AT serum levels. Since anti-AAV2 and -AAV5 antibodies prevalent in humans may limit the use of these common serotypes in gene therapy, we screened 25 AAV vectors derived from humans and nonhuman primates for α1AT expression following intrapleural administration to mice. The rhesus AAVrh.10 serotype yielded the highest levels and was chosen for further study. Following intrapleural administration, 77{\%} of total body transgene expression was in the chest wall, diaphragm, lung, and heart. Intrapleural administration of AAVrh.10α1AT provided long-term, therapeutic α1AT expression in mice, although higher doses were required to achieve therapeutic levels in female mice than in male mice. Intrapleural administration of AAVrh.10α1AT produced the same levels in AAV2/AAV5-preimmune and naive mice. In mice administered with AAV5α1AT and subsequently {"}boosted{"} with the AAVrh.10α1AT vector, serum levels were increased by 300{\%}. These data indicate that AAVrh.10 is the most effective known AAV vector for intrapleural gene delivery and has the advantage of circumventing human immunity to AAV.",
keywords = "α1-antitrypsin, Adeno-associated virus, Gene therapy, Neutralizing antibodies, Pleura, Serotypes",
author = "De, {Bishnu P.} and Adriana Heguy and Hackett, {Neil R.} and Barbara Ferris and Leopold, {Philip L.} and John Lee and Lorraine Pierre and Guangping Gao and Wilson, {James M.} and Ronald Crystal",
year = "2006",
month = "1",
day = "1",
doi = "10.1016/j.ymthe.2005.09.003",
language = "English",
volume = "13",
pages = "67--76",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - High levels of persistent expression of α1-Antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

AU - De, Bishnu P.

AU - Heguy, Adriana

AU - Hackett, Neil R.

AU - Ferris, Barbara

AU - Leopold, Philip L.

AU - Lee, John

AU - Pierre, Lorraine

AU - Gao, Guangping

AU - Wilson, James M.

AU - Crystal, Ronald

PY - 2006/1/1

Y1 - 2006/1/1

N2 - α1-Antitrypsin (α1AT) deficiency is a genetic disorder causing emphysema if serum α1AT levels are <570 μg/ml. We have shown that intrapleural administration of an AAV5α1AT vector yielded persistent therapeutic α1AT serum levels. Since anti-AAV2 and -AAV5 antibodies prevalent in humans may limit the use of these common serotypes in gene therapy, we screened 25 AAV vectors derived from humans and nonhuman primates for α1AT expression following intrapleural administration to mice. The rhesus AAVrh.10 serotype yielded the highest levels and was chosen for further study. Following intrapleural administration, 77% of total body transgene expression was in the chest wall, diaphragm, lung, and heart. Intrapleural administration of AAVrh.10α1AT provided long-term, therapeutic α1AT expression in mice, although higher doses were required to achieve therapeutic levels in female mice than in male mice. Intrapleural administration of AAVrh.10α1AT produced the same levels in AAV2/AAV5-preimmune and naive mice. In mice administered with AAV5α1AT and subsequently "boosted" with the AAVrh.10α1AT vector, serum levels were increased by 300%. These data indicate that AAVrh.10 is the most effective known AAV vector for intrapleural gene delivery and has the advantage of circumventing human immunity to AAV.

AB - α1-Antitrypsin (α1AT) deficiency is a genetic disorder causing emphysema if serum α1AT levels are <570 μg/ml. We have shown that intrapleural administration of an AAV5α1AT vector yielded persistent therapeutic α1AT serum levels. Since anti-AAV2 and -AAV5 antibodies prevalent in humans may limit the use of these common serotypes in gene therapy, we screened 25 AAV vectors derived from humans and nonhuman primates for α1AT expression following intrapleural administration to mice. The rhesus AAVrh.10 serotype yielded the highest levels and was chosen for further study. Following intrapleural administration, 77% of total body transgene expression was in the chest wall, diaphragm, lung, and heart. Intrapleural administration of AAVrh.10α1AT provided long-term, therapeutic α1AT expression in mice, although higher doses were required to achieve therapeutic levels in female mice than in male mice. Intrapleural administration of AAVrh.10α1AT produced the same levels in AAV2/AAV5-preimmune and naive mice. In mice administered with AAV5α1AT and subsequently "boosted" with the AAVrh.10α1AT vector, serum levels were increased by 300%. These data indicate that AAVrh.10 is the most effective known AAV vector for intrapleural gene delivery and has the advantage of circumventing human immunity to AAV.

KW - α1-antitrypsin

KW - Adeno-associated virus

KW - Gene therapy

KW - Neutralizing antibodies

KW - Pleura

KW - Serotypes

UR - http://www.scopus.com/inward/record.url?scp=28844483864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844483864&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.09.003

DO - 10.1016/j.ymthe.2005.09.003

M3 - Article

VL - 13

SP - 67

EP - 76

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -